SCHEMBL3486183

SCHEMBL3486183

Cc1ccccc1NC(=O)CN1CCC(N(C(C)C)S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
ALDH1A1 P00352 2/20 0.48
HSD17B10 Q99714 1/20 0.48
DRD4 P21917 2/20 0.47
DRD3 P35462 1/20 0.47
SIGMAR1 Q99720 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
GAA P10253 2/20 0.45
CYP2D6 P10635 3/20 0.45
CYP2C19 P33261 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP2C9 P11712 2/20 0.45
HTT P42858 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
UBE2M P61081 1/20 0.45
DCUN1D1 Q96GG9 1/20 0.45
MAPT P10636 1/20 0.45
CACNA1B Q00975 3/20 0.44
CACNA1C Q13936 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485265 0.91 ALDH1A1 (0.47) LMNAALDH1A1HSD17B10DRD4DRD3
SCHEMBL13541696 0.89 DRD4 (0.48) ALDH1A1DRD4DRD3SMN1; SMN2GAA
SCHEMBL3485824 0.88 ALDH1A1 (0.52) LMNAALDH1A1HSD17B10DRD4SMN1; SMN2
SCHEMBL3485625 0.88 KMT2A (0.51) LMNAALDH1A1HSD17B10DRD4DRD3
SCHEMBL3485705 0.86 ALDH1A1 (0.54) LMNAALDH1A1HSD17B10DRD4DRD3
SCHEMBL3485918 0.85 TSHR (0.56) LMNAALDH1A1HSD17B10DRD4SMN1; SMN2
SCHEMBL3485688 0.84 ALDH1A1 (0.50) LMNAALDH1A1HSD17B10DRD4SMN1; SMN2
SCHEMBL3485872 0.84 CACNA1B (0.47) LMNAALDH1A1HSD17B10SMN1; SMN2GAA
SCHEMBL3485489 0.84 L3MBTL1 (0.51) LMNAALDH1A1HSD17B10SMN1; SMN2GAA
SCHEMBL13002406 0.83 CACNA1B (0.51) LMNASMN1; SMN2GAAKMT2AUBE2M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B LMNA 1608/4885ALDH1A1 2210/4885HSD17B10 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.